FDA grants OsteoSymbionics 510(k) clearance for sterile processing of ClearShield cranial implant product

OsteoSymbionics, innovative designer and manufacturer of patient-specific craniofacial implants, is pleased to announce FDA (U.S. Food and Drug Administration) 510(k) clearance for sterile processing of its signature ClearShield™ cranial implant product, utilizing a novel room temperature peracetic acid/hydrogen peroxide (PAA) vacuum vapor sterilization process. ClearShield™ received its original 510(k) clearance in 2007 to be provided to the hospital as non-sterile with instructions for on-site sterile processing using ethylene Oxide (EtO). Made from polymethyl methacrylate (PMMA), ClearShield™ implants are used in patients who have suffered disease or trauma to the skull, restoring the protective and cosmetic features of the individual's own bone.  

Dorothy C Baunach, CEO of OsteoSymbionics says, "With more and more hospitals discontinuing on-site use of EtO sterilization, it was becoming harder to get our implants to patients in need without the ability to deliver sterile product to the hospital. We required a sterilization solution that enabled us to deliver sterile product to hospitals in a timely manner and found REVOX® Sterilization Solutions', a Cantel Medical Corp. business, which offered the right technology and all the resources we needed to help our small, but well-respected company, work toward this ideal solution. We are pleased to be able fill the needs of the patients while relieving the hospital of the EtO sterilization process."






The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
Research highlights problems with titanium based nanoparticles in joint implants